No Structure Information
This entry has no structure information.
To add it, be sure the Wikipedia entry contains a valid CAS number in its "Chembox", "Chembox new", "Drugbox", or "Explosivebox" template.
Even with a valid CAS number, structural information may not appear because of limitations in Chempedia's database. Stay tuned for developments in this area.
Etravirine (formerly known as TMC-125, brand name Intelence) is a drug approved in the United States for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTIs). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine. Etravirine is marketed by Tibotec, a subsidiary of Johnson & Johnson. On January 2008, the Food and Drug Administration approved its use for patients with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008. It was also approved for use in Canada on April 1, 2008.
3 edits since May 19, 2008. Last edited Jul 09, 2008 by Carlo Banez (49).
This Compound Monograph is licensed under the GNU Free Documentation License and uses material from the Wikipedia article Etravirine. See this site's terms for details.